Sobhana Babu Boga, Yongqi Deng, Liang Zhu, Yang Nan, Alan B Cooper, Gerald W Shipps, Ronald Doll, Neng-Yang Shih, Hugh Zhu, Robert Sun, Tong Wang, Sunil Paliwal, Hon-Chung Tsui, Xiaolei Gao, Xin Yao, Jagdish Desai, James Wang, Abdul Basit Alhassan, Joseph Kelly, Mehul Patel, Kiran Muppalla, Subrahmanyam Gudipati, Li-Kang Zhang, Alexei Buevich, David Hesk, Donna Carr, Priya Dayananth, Stuart Black, Hong Mei, Kathleen Cox, Bradley Sherborne, Alan W Hruza, Li Xiao, Weihong Jin, Brian Long, Gongjie Liu, Stacey A Taylor, Paul Kirschmeier, William T Windsor, Robert Bishop, Ahmed A Samatar
The emergence and evolution of new immunological cancer therapies has sparked a rapidly growing interest in discovering novel pathways to treat cancer. Toward this aim, a novel series of pyrrolidine derivatives (compound 5 ) were identified as potent inhibitors of ERK1/2 with excellent kinase selectivity and dual mechanism of action but suffered from poor pharmacokinetics (PK). The challenge of PK was overcome by the discovery of a novel 3( S )-thiomethyl pyrrolidine analog 7 . Lead optimization through focused structure-activity relationship led to the discovery of a clinical candidate MK-8353 suitable for twice daily oral dosing as a potential new cancer therapeutic...
July 12, 2018: ACS Medicinal Chemistry Letters